385 related articles for article (PubMed ID: 1913552)
1. Different genomic and metabolic patterns between mass screening-positive and mass screening-negative later-presenting neuroblastomas.
Nakagawara A; Zaizen Y; Ikeda K; Suita S; Ohgami H; Nagahara N; Sera Y; Akiyama H; Kawakami K; Uchino J
Cancer; 1991 Nov; 68(9):2037-44. PubMed ID: 1913552
[TBL] [Abstract][Full Text] [Related]
2. Neuroblastoma detected by mass screening: the Tumor Board's role in its treatment.
Okazaki T; Kohno S; Mimaya J; Hasegawa S; Urushihara N; Yoshida A; Kawano S; Kusafuka J; Horikoshi Y; Takashima Y; Aoki K; Hamazaki M
Pediatr Surg Int; 2004 Jan; 20(1):27-32. PubMed ID: 14689211
[TBL] [Abstract][Full Text] [Related]
3. Mass screening for neuroblastoma: quo vadis? A 9-year experience from the Pediatric Oncology Study Group of the Kyushu area in Japan.
Suita S; Zaizen Y; Sera Y; Takamatsu H; Mizote H; Ohgami H; Kurosaki N; Ueda K; Tasaka H; Miyazaki S; Sugimoto T; Kawakami K; Tsuneyoshi M; Yano H; Akiyama H; Ikeda K
J Pediatr Surg; 1996 Apr; 31(4):555-8. PubMed ID: 8801312
[TBL] [Abstract][Full Text] [Related]
4. [Amplification of the N-myc cellular oncogene in neuroblastoma. Relation to other tumor markers].
Verdona G; Garaventa A; Coviello DA; Cornaglia-Ferraris P; Tonini GP
Boll Ist Sieroter Milan; 1986; 65(4):304-8. PubMed ID: 3790277
[TBL] [Abstract][Full Text] [Related]
5. Amplification of N-myc gene and increase of urinary VMA and HVA in patients with neuroblastic tumors.
Akimaru K; Shoji T; Fukunaga Y; Yamamoto M; Ishizaki R; Nomura N
Nihon Ika Daigaku Zasshi; 1994 Apr; 61(2):148-53. PubMed ID: 8195324
[TBL] [Abstract][Full Text] [Related]
6. Outcome of infants with neuroblastoma detected by mass screening and surgically treated in Shiga Prefecture, Japan: what is the role of surgery?
Hase T; Ohta S; Tani T; Mizukuro T; Mekata E; Naitoh H; Shimadera S; Fujino S; Taga T
Pediatr Surg Int; 2002 Sep; 18(5-6):289-94. PubMed ID: 12415341
[TBL] [Abstract][Full Text] [Related]
7. N-myc oncogene and stage IV-S neuroblastoma. Preliminary observations on ten cases.
Nakagawara A; Sasazuki T; Akiyama H; Kawakami K; Kuwano A; Yokoyama T; Kume K
Cancer; 1990 May; 65(9):1960-7. PubMed ID: 2196987
[TBL] [Abstract][Full Text] [Related]
8. N-myc oncogene and urinary catecholamines in children with neuroblastoma.
Barontini M; Gutiérrez MI; Levin G; Mur N; Diez B
Med Pediatr Oncol; 1993; 21(7):499-504. PubMed ID: 8341218
[TBL] [Abstract][Full Text] [Related]
9. Problems of mass screening for neuroblastoma: analysis of false-negative cases.
Ishimoto K; Kiyokawa N; Fujita H; Yabuta K; Ohya T; Miyano T; Shinohara T; Sera Y
J Pediatr Surg; 1990 Apr; 25(4):398-401. PubMed ID: 2329455
[TBL] [Abstract][Full Text] [Related]
10. Cases of neuroblastoma missed by the mass screening programs.
Nishi M; Miyake H; Takeda T; Takasugi N; Sato Y; Hanai J; Kawai T
Pediatr Res; 1989 Dec; 26(6):603-7. PubMed ID: 2602040
[TBL] [Abstract][Full Text] [Related]
11. The relationship between homovanillic/vanillylmandelic acid ratios and prognosis in neuroblastoma.
Nishi M; Miyake H; Takeda T; Hanai J; Fujita K; Ichimiya H; Tanaka T; Hirama T; Ishikawa Y; Kudoh T; Azuma H; Takase A
Oncol Rep; 1998; 5(3):631-3. PubMed ID: 9538165
[TBL] [Abstract][Full Text] [Related]
12. Serial measurement of urinary VMA and HVA levels from one infant: a study for neuroblastoma mass screening.
Sawada T; Numata K; Hirata S
J Pediatr Surg; 1992 Apr; 27(4):452-5. PubMed ID: 1522454
[TBL] [Abstract][Full Text] [Related]
13. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma.
Tuchman M; Ramnaraine ML; Woods WG; Krivit W
Pediatrics; 1987 Feb; 79(2):203-5. PubMed ID: 3808793
[TBL] [Abstract][Full Text] [Related]
14. One hundred neuroblastomas detected through a mass screening system in Japan.
Hachitanda Y; Ishimoto K; Hata J; Shimada H
Cancer; 1994 Dec; 74(12):3223-6. PubMed ID: 7982186
[TBL] [Abstract][Full Text] [Related]
15. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project.
Takeuchi LA; Hachitanda Y; Woods WG; Tuchman M; Lemieux B; Brisson L; Bernstein M; Brossard J; Leclerc JM; Byrne TD
Cancer; 1995 Dec; 76(11):2363-71. PubMed ID: 8635044
[TBL] [Abstract][Full Text] [Related]
16. Hormonal activity may predict aggressive behavior in neuroblastoma.
Zambrano E; Reyes-Múgica M
Pediatr Dev Pathol; 2002; 5(2):190-9. PubMed ID: 11910515
[TBL] [Abstract][Full Text] [Related]
17. Screening for neuroblastoma: a review of the evidence.
Chamberlain J
J Med Screen; 1994 Jul; 1(3):169-75. PubMed ID: 8790511
[TBL] [Abstract][Full Text] [Related]
18. Urinary vanillylmandelic acid and homovanillic acid levels in randomly-sampled urine for the mass screening of neuroblastoma.
Nishi M; Miyake H; Takeda T; Takasugi N; Hanai J; Kawai T
Jpn J Clin Oncol; 1990 Sep; 20(3):268-70. PubMed ID: 2255102
[TBL] [Abstract][Full Text] [Related]
19. Tumour markers are poor predictors for relapse or progression in neuroblastoma.
Simon T; Hero B; Hunneman DH; Berthold F
Eur J Cancer; 2003 Sep; 39(13):1899-903. PubMed ID: 12932669
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic markers in infants with disseminated neuroblastoma: a retrospective analysis from the Italian Cooperative Group for Neuroblastoma.
Di Cataldo A; Dau D; Conte M; Parodi S; De Bernardi B; Giuliano M; Pession A; Viscardi E; Luksch R; Castellano A; Bertuna G; Haupt R;
Med Sci Monit; 2009 Jan; 15(1):MT11-8. PubMed ID: 19114976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
